Monte Rosa Therapeutics
GLUE15.3806.90% ( -1.140 )
Q1 FY2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Preview: Monte Rosa Therapeutics(GLUE) predict that the Revenue is 4.21 M (-95.04%), Miss estimate;the EBIT is -50.03 M (-213.6%), Miss estimate;the EPS is -0.45 (-179%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.00B95.04%
0.01B86.59%
-0.01B8.45%
EBITMiss expectations
-0.05B213.62%
-0.04B196.40%
-0.01B17.22%
EPSMiss expectations
-0.45178.95%
-0.3796166.60%
-0.070412.35%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf